Search
Vaccines Treatment Options
A collection of 940 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
229 - 240 of 940
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
Completed
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
Gender:
ALL
Ages:
Between 15 years and 25 years
Trial Updated:
06/07/2024
Locations: GSK Investigational Site, Jonesboro, Arkansas +68 locations
Conditions: Meningitis, Meningococcal
COVID-19 3rd Dose Vaccine in Transplant Patients
Terminated
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: University of Miami, Miami, Florida
Conditions: Covid19
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
Completed
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
Gender:
ALL
Ages:
Between 6 years and 64 years
Trial Updated:
05/30/2024
Locations: Valleywise Health Comprehensive Health Center, Phoenix, Arizona +7 locations
Conditions: Influenza, COVID-19
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Completed
This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ in previously mRNA COVID-19 vaccinated adult participants ≥18 years of age and baseline SARS CoV-2 seropositive COVID-19 vaccine naïve participants ≥18 years of age.
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
05/29/2024
Locations: AMR, Mobile, Alabama +29 locations
Conditions: COVID-19
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
Recruiting
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes (locally advanced). PDS0101 is a vaccine made from specific peptides that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Completed
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/22/2024
Locations: Optimal Research Alabama, Huntsville, Alabama +5 locations
Conditions: Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
Completed
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/22/2024
Locations: Site 14, Denver, Colorado +55 locations
Conditions: Influenza
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Completed
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor receptor 2 (HER2) positive breast or ovarian cancer who are receiving trastuzumab. Giving booster vaccines made from HER2 peptides may help increase HER2 specific immunity and immune memory cells.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/21/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
Completed
This study was designed to evaluate the safety and tolerability of a single dose of V114 when administered concomitantly and non-concomitantly (i.e., 30 days after) with influenza vaccine. It also evaluated whether V114 can be administered concomitantly with influenza vaccine without impairing the antibody response to the 15 serotypes contained in V114 and to the 4 influenza viruses contained in the seasonal inactivated quadrivalent influenza vaccine (QIV). The primary hypotheses state that immu... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/20/2024
Locations: Achieve Clinical Research, LLC ( Site 0046), Birmingham, Alabama +44 locations
Conditions: Pneumococcal Infections
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Completed
The primary objectives of the study were:
* To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus.
* To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-naïve participants.
The secondary objectives of the study were:
* To quantify the amount of vaccine virus shed by each participan... Read More
Gender:
ALL
Ages:
Between 6 months and 18 months
Trial Updated:
05/20/2024
Locations: Matrix Clinical Research-Site Number:8400012, Gardena, California +28 locations
Conditions: Respiratory Syncytial Virus Infection
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Recruiting
This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced stage). Labvax 3(22)-23 is designed to target a specific antigen (labyrinthin), which is a protein found on the surface of adenocarcinoma tumor cells. Labyrinthin is a protein that is not expressed on normal cells in the skin, lungs, salivary glands, pancreas, nor o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
The Impact of COVID-19 on Maternal and Neonatal Outcomes
Recruiting
The novel coronavirus (SARS-CoV-2) infection (COVID-19) has caused a worldwide pandemic. There is still much that is unknown regarding the virus, especially its effects on pregnancy, the fetus, and the neonate. This study seeks to evaluate adverse pregnancy and neonatal outcomes related to COVID-19 infection.
The FDA has authorized emergency use authorization for the SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccines from Pfizer and Moderna. Pregnant women were excluded from the Phase III cl... Read More
Gender:
FEMALE
Ages:
Between 14 years and 55 years
Trial Updated:
05/16/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: COVID-19, Pregnancy; Infection
229 - 240 of 940